PBAC's latest decision on Pertuzumab: Recommended with restriction (2025). Considered for Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early stage (>2 cm in diameter or node positive) early breast cancer, in combination with trastuzumab and chemotherapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
5
first 2014
PBS spend
$69M
21,997 scripts · 2024
Eligible population
Adults with HER2-positive, locally advanced, inflammatory or early stage (>2 cm in diameter or lymph node positive) early breast cancer receiving neoadjuvant treatment in combination with trastuzumab and chemotherapy
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
pCR
Key trials
NEOSPHERE, TRYPHAENA, PEONY, I-SPY2
Comparator
trastuzumab in combination with chemotherapy (T+Chemo)
Economic model
CUA
ICER note
ICER value is redacted/not published in the public text
ICER (historical)
$45k/QALY–$105k/QALY across 2 submissions (2014–2018) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
PBS expenditure
The Australian government paid $69M in PBS benefits for Pertuzumab in 2024 across 21,997 scripts, at $3,148 per script.
Submission history
Mar 2014: Not recommended · Authority Required — ICER $75k/QALY
Jul 2018: Recommended with restriction · Restricted — ICER $105k/QALY
Mar 2019: Recommended with restriction · Authority Required
Mar 2020: Recommended with restriction · Authority Required
Mar 2025: Recommended with restriction · Authority Required